ClinicalTrials.gg
CompletedNCT00149994Updated Apr 12, 2011Results posted

Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients

A Phase 4 interventional study of Cyclosporine A and Tacrolimus in Liver Transplant, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-04-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether cyclosporine A (in a micro emulsion formulation) monitored by sample taken 2 hour after oral dose (C-2h) will show equivalent or superior efficacy compared to tacrolimus monitored by pre-dose blood concentration (C-0h). In addition this study will assess the safety and tolerability of a cyclosporine A regimen based on C-2h monitoring in comparison to the standard tacrolimus regimen.

02

Conditions studied

  • Liver Transplant

Keywords

  • Liver transplant, adults, C2 monitoring
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • About to undergo a primary liver transplant (including living donor, non-heart beating donor and split liver).
  • Age between 18 and 75 years.
  • Expected to be able to receive the first oral dose of CNI within the first 24 hours post-transplantation (Tx)

Exclusion criteria

Exclusion Criteria:

  • This is a multi-organ transplant or if the patient has previously been transplanted with any other organ.
  • Urine production is \<200 ml within 12 hours after reperfusion of the graft
  • Severe coexisting disease is present or if any unstable medical condition is present which could affect the study objectives.

Other protocol-defined exclusion criteria applied

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Cyclosporine A

    Cyclosporine A was given in a twice-daily schedule at 12-hour intervals. It was administered within the first 4 hours post-operatively (study day 1), at an initial dose of 10-15mg/kg/day in two doses, as close as possible to 15mg/kg/day. After the first oral administration, the dose of Cyclosporine A was adjusted to bring the sample taken 2 hours after oral dose (C-2h) level into the target range by Days 3-5 post-transplantation. C-2h target ranges post-transplantation: 0-3 months: range of 800-1200 ng/ml with midpoint of 1000 ng/ml; 4-6 months: range of 700-900 ng/ml with midpoint of 800 ng/ml; \> 6 months: range of 500-700 ng/ml with midpoint of 600 ng/ml is recommended. During the course of the study, the dose of Cyclosporine A was adjusted as necessary to achieve and maintain the C-2h blood Cyclosporine A (CsA) concentrations within the target ranges.

    Drug: Cyclosporine A · Drug: Basiliximab · Drug: Methylprednisolone · Drug: Prednisone

  • Active comparator
    Tacrolimus

    Tacrolimus was given on a twice-daily schedule at 12-hour intervals which had to be maintained throughout the study period. Tacrolimus was administered within the first 24 hrs postoperatively (Study Day 1) at an initial dose of 0.1-0.15 mg/kg/day in two divided oral doses either by mouth or via an enteral feeding tube until the patient can swallow. The initial dosing level was determined by the patient's overall post-operative condition. During the course of the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain the pre-dose blood concentration (C-0h) (trough) tacrolimus concentrations. C-0h target ranges post-transplantation: 0-3 months: 10-15 ng/ml; 4-6 months: 5-10 ng/ml; \> 6 months: range of 5-10 ng/ml is recommended.

    Drug: Tacrolimus · Drug: Basiliximab · Drug: Methylprednisolone · Drug: Prednisone

Interventions

  • Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.

  • Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery

  • Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation.

    A BPAR is defined when the investigator had a suspicion of an acute rejection, where the final clinical diagnosis confirmed the occurrence of an acute rejection, where a biopsy was performed that confirmed the presence of an acute rejection, and where anti-rejection treatment intervention was initiated. The efficacy measured the first rejections (clinically and biopsy proven rejections) at 3 months.

    Time frame: Month 3

07

Results

Posted Feb 14, 2011

Participant flow

Participant flow — Overall Study
MilestoneCyclosporine ATacrolimus
Started8586
Completed8485
Not completed11
Withdrew: Administrative problems:10
Withdrew: Protocol violation01

Outcome measures

PrimaryPercentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation.

A BPAR is defined when the investigator had a suspicion of an acute rejection, where the final clinical diagnosis confirmed the occurrence of an acute rejection, where a biopsy was performed that confirmed the presence of an acute rejection, and where anti-rejection treatment intervention was initiated. The efficacy measured the first rejections (clinically and biopsy proven rejections) at 3 months.

Time frame:
Month 3
Reported as:
Number · Percentage of Participants
Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation.
Percentage of ParticipantsCyclosporine ATacrolimus
Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation.33.332.9

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tacrolimus—42/86 (48.8%)84/86 (97.7%)
Cyclosporine A—33/85 (38.8%)85/85 (100%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventTacrolimusCyclosporine A
PyrexiaGeneral disorders11/864/85
Biliary anastomosis complicationInjury, poisoning and procedural complications3/863/85
VomitingGastrointestinal disorders3/860/85
CholangitisHepatobiliary disorders3/862/85
AscitesGastrointestinal disorders0/862/85
DiarrhoeaGastrointestinal disorders0/862/85
CholestasisHepatobiliary disorders0/862/85
HyperglycaemiaMetabolism and nutrition disorders0/862/85
Back painMusculoskeletal and connective tissue disorders2/862/85
Nephropathy toxicRenal and urinary disorders0/862/85
Most frequent other events
Showing 10 of 73
Most frequent other events
EventTacrolimusCyclosporine A
DiarrhoeaGastrointestinal disorders26/8654/85
InsomniaPsychiatric disorders30/8646/85
OedemaGeneral disorders41/8637/85
NauseaGastrointestinal disorders40/8639/85
Enterococcal infectionInfections and infestations28/8637/85
AscitesGastrointestinal disorders29/8635/85
Staphylococcal infectionInfections and infestations34/8633/85
PyrexiaGeneral disorders25/8633/85
Procedural painInjury, poisoning and procedural complications22/8633/85
HypertensionVascular disorders33/8621/85

Baseline characteristics

Age Continuous
Age Continuous(Years)Cyclosporine ATacrolimusTotal
Mean48.1 ± 12.06949.9 ± 9.88648.98 ± 11.029
Sex: Female, Male
Sex: Female, Male(Participants)Cyclosporine ATacrolimusTotal
Female313061
Male5355108
08

Study locations

1 site
  • Novartis
    Basel, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Dec 2002
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Feb 14, 2011
Last update
Apr 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00149994
First posted
Sep 8, 2005
Start date
Dec 2002
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Feb 14, 2011
Last update
Apr 12, 2011

Study contacts

Novartis
study director · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion